2019
Assessment of an electronic and clinician-delivered brief intervention on cigarette, alcohol and illicit drug use among women in a reproductive healthcare clinic
Forray A, Martino S, Gilstad-Hayden K, Kershaw T, Ondersma S, Olmstead T, Yonkers KA. Assessment of an electronic and clinician-delivered brief intervention on cigarette, alcohol and illicit drug use among women in a reproductive healthcare clinic. Addictive Behaviors 2019, 96: 156-163. PMID: 31100713, PMCID: PMC6579708, DOI: 10.1016/j.addbeh.2019.05.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingAlcohol-Related DisordersAmbulatory Care FacilitiesCigarette SmokingDiagnosis, Computer-AssistedFemaleHealth PersonnelHumansMass ScreeningMiddle AgedMotivational InterviewingReferral and ConsultationReproductive Health ServicesSmoking ReductionSubstance-Related DisordersTherapy, Computer-AssistedTreatment OutcomeYoung AdultConceptsEnhanced usual careIllicit drug useE-SBIRTDrug useCigarette useBrief interventionIllicit drugsAlcohol useSubstance useReproductive-age womenReproductive health clinicsGreater reductionSubstance use disordersReproductive healthcare clinicsUse of cigarettesPrimary substancePrimary substance useClinician-delivered interventionSBIRT interventionOverall substance useUsual careMonth 3Present studyReproductive yearsHealth clinics
2015
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72: 1037-1044. PMID: 26351969, PMCID: PMC4811029, DOI: 10.1001/jamapsychiatry.2015.1472.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderSymptom-onset dosingSerotonin reuptake inhibitorsDays of mensesSSRI withdrawalSymptom onsetSymptomatic daysMenstrual cycleClinical trialsDysphoric disorderOutcome measuresScale scoreSRI treatmentTreatment of PMDDClinical Global Impression ScaleAbrupt treatment cessationDepressive Symptomatology-ClinicianTotal DRSP scoresSecondary outcome measuresPrimary outcome measureGlobal Impression ScaleIDS-C scoresUniversity Medical CenterSertraline hydrochlorideBeginning of menses
2005
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstetrics And Gynecology 2005, 106: 492-501. PMID: 16135578, DOI: 10.1097/01.aog.0000175834.77215.2e.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPlacebo groupSymptom scoresDysphoric disorderNew low dose oral contraceptiveLow-dose oral contraceptivesBehavioral symptom scoresActive treatment groupDaily symptom scoresPhysical symptom scoresEthinyl estradiol groupInactive pillsOral contraceptivesEstradiol groupClinical trialsEthinyl estradiolTreatment cyclesTotal Daily RecordI. EfficacyDrospirenoneSymptomsPill formulationDisordersOCP formulationsPlaceboPretreatment pattern of symptom expression in premenstrual dysphoric disorder
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal Of Affective Disorders 2005, 85: 275-282. PMID: 15780697, DOI: 10.1016/j.jad.2004.10.004.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPMDD symptomsMenstrual cycleDysphoric disorderPatient variabilityIntermittent dosing strategyOnset of menstruationDSM-IV criteriaPatients' durationAnxiety/tensionSertraline treatmentDRSP scoresPatient daysDosing strategiesSevere symptomsDay 2SymptomsTreatment studiesPretreatment patternAnger/irritabilityMood swingsMore daysWomenSymptom expressionTreatment implications
2003
Premenstrual disorders: bridging research and clinical reality
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Archives Of Women's Mental Health 2003, 6: 287-292. PMID: 14628181, DOI: 10.1007/s00737-003-0026-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersFemaleHumansPatient Acceptance of Health CarePatient SelectionPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSelf-AssessmentSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeConceptsPremenstrual dysphoric disorderPremenstrual symptomsTreatment resultsBrief Patient Health QuestionnaireConcurrent psychiatric conditionsOb-gyn settingsStatistical Manual IV criteriaSerotonin reuptake inhibitorsUsual care settingsPatient Health QuestionnaireMinor depressive disorderActual clinical practiceTypes of symptomsEligible womenPatient characteristicsReuptake inhibitorsOpen trialSymptomatic subgroupCurrent comorbidityIV criteriaClinical trialsDepressive disorderHealth QuestionnaireTypical patientDysphoric disorder
2002
Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
Halbreich U, Bergeron R, Yonkers K, Freeman E, Stout A, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics And Gynecology 2002, 100: 1219-29. PMID: 12468166, DOI: 10.1016/s0029-7844(02)02326-8.Peer-Reviewed Original Research
2001
An Eight-Year Longitudinal Comparison of Clinical Course and Characteristics of Social Phobia Among Men and Women
Yonkers KA, Dyck IR, Keller MB. An Eight-Year Longitudinal Comparison of Clinical Course and Characteristics of Social Phobia Among Men and Women. Psychiatric Services 2001, 52: 637-643. PMID: 11331798, DOI: 10.1176/appi.ps.52.5.637.Peer-Reviewed Original ResearchConceptsHealth-related qualityHarvard/Brown Anxiety Research ProgramSuicide attemptsSocial phobiaComorbid substance use disorderPoorer baseline functioningLower Global AssessmentPercent of menPercent of womenSubstance use disordersPotential sex differencesComplete remissionRemission rateClinical courseChronic courseEight-year study periodChronic disordersHigh prevalenceObservational studyFunctioning scoresUse disordersBaseline functioningConcurrent agoraphobiaGreater chronicityGlobal assessment